Research and Markets: Rotavirus Infections Therapeutic Development - Pipeline Review & Analysis, H2 2015

Research and Markets (http://www.researchandmarkets.com/research/68dl3q/rotavirus) has announced the addition of the "Rotavirus Infections - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Rotavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rotavirus Infections and special features on late-stage and discontinued projects.

Key Topics Covered:

  • The report provides a snapshot of the global therapeutic landscape of Rotavirus Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Rotavirus Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Rotavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Rotavirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Benefits of this Report:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Rotavirus Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Rotavirus Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned:

  • Beijing Minhai Biotechnology Co., Ltd
  • Biological E. Limited
  • CureVac GmbH
  • Medicago Inc.
  • Nanotherapeutics, Inc.
  • SEEK Group
  • Serum Institute of India Limited
  • Shantha Biotechnics Limited
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited

For more information visit http://www.researchandmarkets.com/research/68dl3q/rotavirus

Contacts:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious Diseases

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.